Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | RHEB | Q15382 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 4/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | PNMT | P11086 | 2/20 | 0.38 |
| ▸ | IDO1 | P14902 | 2/20 | 0.38 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.36 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.35 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.35 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18590393 | 0.82 | TSHR (0.45) | ALDH1A1RHEBTSHRCYP1A2CYP3A4 | |
| SCHEMBL24166 | 0.80 | TSHR (0.45) | ALDH1A1TSHRTP53TDP1SMN1; SMN2 | |
| SCHEMBL2723162 | 0.77 | ALDH1A1 (0.45) | ALDH1A1CYP1A2IDO1MRGPRX4KDM4E | |
| SCHEMBL521826 | 0.77 | MRGPRX4 (0.40) | TSHRCYP1A2SMN1; SMN2IDO1MRGPRX4 | |
| SCHEMBL14237478 | 0.77 | SLC6A2 (0.33) | SLC6A2SLC6A4SLC6A3HTR1ATAAR1 | |
| SCHEMBL1125159 | 0.77 | TSHR (0.48) | ALDH1A1TSHRCYP3A4TP53TDP1 | |
| SCHEMBL6325195 | 0.77 | RHEB (0.60) | ALDH1A1RHEBTSHRCYP1A2CYP3A4 | |
| SCHEMBL11766505 | 0.77 | PNMT (0.48) | ALDH1A1RHEBTSHRCYP1A2CYP3A4 | |
| SCHEMBL315903 | 0.73 | ALDH1A1 (0.43) | ALDH1A1RHEBTSHRCYP1A2CYP3A4 | |
| SCHEMBL8669453 | 0.73 | ALDH1A1 (0.43) | ALDH1A1RHEBTSHRCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 223 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3571199-B1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | REVOLUTION MEDICINES INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2026-03-03 | — | — | US | disclosed |
| US-12435068-B2 | Anthelmintic compounds | ELANCO ANIMAL HEALTH GMBH (DE) | 2025-10-07 | — | — | US | disclosed |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | Revolution Medicines, Inc. (US) | 2025-07-22 | — | — | US | disclosed |
| US-20250163052-A1 | cGAS INHIBITORS AND USES THEREOF | CORNELL UNIVERSITY | 2025-05-22 | — | — | US | disclosed |
| US-12209074-B2 | SHP2 phosphatase allosteric inhibitor | BEIJING SHENOGEN PHARMA GROUP LTD. (CN) | 2025-01-28 | — | — | US | disclosed |
| CN-111201223-B | Octahydrocyclopenta [ c ] pyrrole allosteric inhibitors of SHP2 | 克鲁松制药公司 | 2024-07-09 | — | — | CN | disclosed |
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT | 2024-06-20 | — | — | US | disclosed |
| CN-117916242-A | SHP2 inhibitors and uses thereof | 治纳辅医药科技有限公司 | 2024-04-19 | — | — | CN | disclosed |
| WO-2001055085-A1 | PROPIONIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT OF DIABETES AND OBESITY | NOVO NORDISK A/S (DK) | 2001-08-02 | — | — | WO | disclosed |
| WO-1999064045-A9 | NOVEL THERAPEUTIC AGENTS FOR MEMBRANE TRANSPORTERS | ADVANCED MEDICINE INC (US) | 2001-07-05 | — | — | WO | disclosed |
| EP-1085890-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | Advanced Medicine, Inc. (US) | 2001-03-28 | — | — | EP | disclosed |
| WO-2000077001-A1 | SUBSTITUTED HETEROCYCLE FUSED GAMMA-CARBOLINES | DU PONT PHARMACEUTICALS COMPANY (US) | 2000-12-21 | — | — | WO | disclosed |
| WO-1999063984-A1 | NOVEL SODIUM CHANNEL DRUGS AND USES | ADVANCED MEDICINE, INC. (US) | 1999-12-16 | — | — | WO | disclosed |
| EP-0691966-B1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX INC (US) | 1998-09-09 | — | — | EP | disclosed |
| EP-0691966-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1996-01-17 | — | — | EP | disclosed |
| US-5455252-A | Antiinflammatory agent, immunosuppressant, antiallergen, skin disorders, bronchodilator, analgesic | SYNTEX (U.S.A.) INC. (US) | 1995-10-03 | — | — | US | disclosed |
| WO-1994022852-A1 | QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS | SYNTEX (U.S.A.) INC. (US) | 1994-10-13 | — | — | WO | disclosed |
| WO-1993016195-A1 | CHEMILUMINESCENT ENHANCERS | BRITISH TECHNOLOGY GROUP LTD. (GB) | 1993-08-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199616-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN18, PTPN1, PTPN2 | ALDH1A1 4439/4885RHEB 682/4885TSHR 1965/4885 |
| US-12365688-B2 | Substituted pyrazolopyrazines, imidazopyrazines and [1,2,4]triazolopyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN2, PTPN1 | ALDH1A1 3739/4885RHEB 1366/4885TSHR 1390/4885 |
| US-20250163052-A1 | cGAS INHIBITORS AND USES THEREOF | CGAS, STING1, MAVS | ALDH1A1 4215/4885RHEB 465/4885TSHR 4046/4885 |
| US-20260103469-A1 | BICYCLIC COMPOUNDS AS ALLOSTERIC SHP2 INHIBITORS | PTPN5, PTPN6, PTPN1 | ALDH1A1 4202/4885RHEB 1709/4885TSHR 243/4885 |
| US-12209074-B2 | SHP2 phosphatase allosteric inhibitor | PTPN1, PTPN5, PTPN18 | ALDH1A1 4077/4885RHEB 1011/4885TSHR 1203/4885 |
| US-12435068-B2 | Anthelmintic compounds | H1-10, HRH2, HRH1 | ALDH1A1 457/4885RHEB 2626/4885TSHR 1713/4885 |
| US-12565476-B2 | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric SHP2 inhibitors | PTPN5, PTPN6, PTPN2 | ALDH1A1 4358/4885RHEB 1561/4885TSHR 250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.